Intranasal HGF administration ameliorates the physiologic and morphologic changes in lung emphysema

Area of Science:

• Pulmonary Medicine
• Regenerative Medicine
• Stem Cell Biology

Background:

• Emphysema is a chronic lung disease characterized by alveolar destruction.
• Hepatocyte Growth Factor (HGF) has known roles in cell proliferation and wound healing.
• The therapeutic potential of HGF in emphysema and its effect on stem cells remain underexplored.

Purpose of the Study:

• To investigate the therapeutic efficacy of intranasal HGF in an elastase-induced emphysema mouse model.
• To determine the role of stem/progenitor cells in HGF-mediated emphysema treatment.

Main Methods:

• Mice with established emphysema received intranasal HGF twice weekly for 1-4 weeks.
• Lung function (static lung compliance) and morphology (airspace enlargement, alveolar destruction) were assessed.
• Expression of stem cell markers (c-kit, Sca-1, CD34) and proliferation markers (PCNA, cytokeratin-19) were analyzed.

Main Results:

• HGF treatment significantly ameliorated airspace enlargement and alveolar wall destruction.
• Lung compliance returned to normal levels within two weeks of HGF administration.
• HGF influenced stem cell populations and increased epithelial proliferation markers, indicating alveolar regeneration.

Conclusions:

• Intranasal HGF effectively reverses physiological and morphometric changes in a mouse model of emphysema.
• HGF treatment appears to work by mobilizing stem cells and promoting alveolar regeneration.
• This study suggests a promising nonsurgical therapeutic approach for emphysema, with potential human applications.